JCJordi Curto

Jordi Curto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jordi Curto has a total of 260 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Podzamczer

    A HIV and STD Unit, Infectious Disease Service , Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL) , L'Hospitalet de Llobregat , Spain

    16 shared publications
  • Elena Ferrer

    HIV and STD Unit, Department of Infectious Diseases

    10 shared publications
  • Pere Domingo

    D Department of Infectious Diseases , Hospitals Universitaris Arnau de Vilanova & Santa Maria, Institut de Recerca Biomèdica (IRBLLEIDA), Universitat de Lleida , Lleida , Spain

    7 shared publications
  • Esteban Ribera

    Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d'Hebron, Barcelona, España

    6 shared publications
  • Arkaitz Imaz

    Bellvitge University Hospital, L'Hospitalet de Llobregat Barcelona Spain

    5 shared publications
  • Maria Saumoy

    HIV Unit, Infectious Disease Department, Bellvitge University Hospital, L'Hospitalet, Barcelona, Spain

    5 shared publications

Latest Publications

  • Open Access

    Study protocol for improving mental health during pregnancy: a randomized controlled low-intensity m-health intervention by midwives at primary care centers

    by Marta Jimenez-Barragan, Amparo del Pino Gutierrez, Jorge Curto Garcia, Olga Monistrol-Ruano, Engracia Coll-Navarro, Oriol Porta-Roda, Gemma Falguera-Puig

    Background: Pregnancy-related anxiety and depression has received considerable attention worldwide. Mental health problems in pregnant women already since early weeks of gestation may have important consequences to the fetus. The necessity for more effective health care pathways, including some early interventions that reduce the overall burden of the childbearing situation appears a key factor for a successful birth and care of the baby. The few studies focalized in interventions, are focused on delivery and postpartum, without taking into account the whole maternity process. Current literature recommends the use of interventions based on new technologies for the treatment of mood disorders, already during the prenatal period. There have been scarce well-designed intervention studies that test technological low-intensity interventions by midwives to address pregnant women’s mental health, diminishing anxiety and depression during pregnancy. Methods/design: Adult pregnant women (weeks 12–14 of gestation) will be recruited and screened from different primary care centers in Catalonia, Spain. Women who pass the initial mental screening will be randomly allocated to the relaxation virtual reality intervention or control group. The intervention aims to improve mental state of pregnant women during pregnancy, work through breathing, mindfulness and muscle relaxation techniques. Women in the control group will receive standard care offered by the public funded maternity services in Catalonia. The primary outcome measures will include the Edinburg Postnatal Depression (EPDS), State Trait Anxiety Inventory (STAI), Symptom Checklist-90 (SCL-90), and the Cambridge Worry Scale (CWS) instruments. Secondary outcome measures will include the Temperament and Character Inventory-Revised (TCI-R) and the Whooley and Generalized Anxiety Disorder-2 (GAD-2) questions. Routinary pregnancy monitoring measures will be also evaluated. Discussion: This study aims to test the efficacy of a low-intensity, midwife-led e-health intervention based on new technologies to work on women’s anxiety and depression during pregnancy. We hypothesize that low-intensity mental health intervention during pregnancy, using an e-health (virtual reality) as a support tool, will be effective in reducing of anxiety, depressive symptoms, and improving satisfaction with pregnancy follow-up. Trial registration: Clinical Trials ID NCT05756205.


  • Open Access

    Factors Predicting Ictal Quality in Bilateral Electroconvulsive Therapy Sessions

    by Aida de Arriba-Arnau, Antonia Dalmau Llitjos, Virginia Soria, Stelania Savino, Neus Salvat-Pujol, Jordi Curto, José Manuel Menchón, Mikel Urretavizcaya

    In electroconvulsive therapy (ECT), ictal characteristics predict treatment response and can be modified by changes in seizure threshold and in the ECT technique. We aimed to study the impact of ECT procedure-related variables that interact during each session and might influence the seizure results. Two hundred and fifty sessions of bilateral ECT in forty-seven subjects were included. Seizure results were evaluated by two different scales of combined ictal EEG parameters (seizure quality index (SQI) and seizure adequacy markers sum (SAMS) scores) and postictal suppression rating. Repeated measurement regression analyses were performed to identify predictors of each session’s three outcome variables. Univariate models identified age, physical status, hyperventilation, basal oxygen saturation, days between sessions, benzodiazepines, lithium, and tricyclic antidepressants as predictors of seizure quality. Days elapsed between sessions, higher oxygen saturation and protocolized hyperventilation application were significant predictors of better seizure quality in both scales used in multivariate models. Additionally, lower ASA classification influenced SQI scores as well as benzodiazepine use and lithium daily doses were predictors of SAMS scores. Higher muscle relaxant doses and lower applied stimulus intensities significantly influenced the postictal suppression rating. The study found several modifiable procedural factors that impacted the obtained seizure characteristics; they could be adjusted to optimize ECT session results.


  • A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain

    by I. Márquez-Rodas, A. Arance, A. Berrocal, C. L. Larios, J. Curto-García, I. X. Campos-Tapias, A. B. Blanca, S. Martin-Algarra

    To describe patient characteristics by disease stage, resectability status and current treatment management after first diagnosis of IIIB to IV1c advanced (AM)/metastatic melanoma (MM).


  • Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy

    by Maria Saumoy, Juan M. Tiraboschi, Jordi Ordoñez-Llanos, Esteban Ribera, Pere Domingo, Josep Mallolas, Jordi Curto, Josep M. Gatell, Daniel Podzamczer

    Background: The objective of this study was to determine the impact of tenofovir or abacavir discontinuation on low-density lipoprotein (LDL) phenotype and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in HIV-infected patients treated with lopinavir/ritonavir plus 2 nucleos(t)ide reverse transcriptase inhibitors (NRTI). Methods: Multicenter, open-label study. Patients were randomized to continue with lopinavir/ritonavir plus 2 NRTI (triple therapy) or to switch to lopinavir/ritonavir plus lamivudine (dual therapy). LDL phenotype (by gradient gel electrophoresis) and Lp-PLA2 (by 2-thio-PAF) were determined at baseline and week 48. Results: Forty-four patients included (triple therapy n = 19, dual therapy n = 25): men 63.6%, age 41.5 years (25–61), Framingham score 4.9% (0.2–22). Tenofovir was part of the regimen in 28 (63.6%) patients. Dual therapy patients were younger (p = 0.013) and had lower baseline apolipoprotein A1 (p = 0.029). At week 48, there were no changes in standard lipid measurements, except ApoA1/Apo B, which increased in dual therapy (p = 0.038) with no differences between arms. At week 48, no change in LDL phenotype was found in either arm. No changes in total Lp-PLA2 activity or the relative distribution of LDL and HDL particles were found at week 48 in either arm. Conclusions: Discontinuing the third nucleos(t)ide, mainly tenofovir and abacavir, in a lopinavir/ritonavir-containing regimen was not associated with a deleterious effect on LDL phenotype nor in Lp-PLA2 activity.

  • Open Access

    HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen

    by Arkaitz Imaz, Javier Martinez-Picado, Jordi Niubó, Angela D. M. Kashuba, Elena Ferrer, Dan Ouchi, Craig Sykes, Nerea Rozas, Laura Acerete, Jordi Curto, et al.

    The objective of this study was to quantify human immunodeficiency virus (HIV) type 1 RNA decay and dolutegravir (DTG) concentrations in the semen of HIV-infected patients receiving DTG-based first-line therapy. This was a prospective, single-arm, open-label study including 15 HIV-1–infected, antiretroviral therapy–naive men starting once-daily treatment with DTG (50 mg) plus abacavir-lamivudine (600/300 mg). HIV-1 RNA was measured in seminal plasma (SP) and blood plasma (BP) at baseline, on days 3, 7, and 14, and at weeks 4, 12, and 24. The HIV-1 RNA decay rate was assessed using nonlinear mixed-effects models. Total and free DTG concentrations were quantified 24 hours after the dose at weeks 4 and 24 by means of a validated liquid chromatography–tandem mass spectrometry method. Viral decay was faster in BP than in SP in the first decay phase (half-life, 4.5 vs 8.6 days; P = .001) with no statistically significant differences in the second phase. HIV-1 RNA suppression (P = .008) due to lower baseline HIV-1 RNA levels. The median total DTG 24 hours after the dose in SP was 119.1 ng/mL (range, 27.2–377 ng/mL), which represents 7.8% of BP exposure. The median DTG free-fraction in SP was 48% of the total drug. Seminal protein-unbound DTG concentrations exceeded the in vitro 50% inhibitory concentration (0.21 ng/mL) by a median of 214-fold. DTG concentrations in SP are sufficient to contribute to rapid seminal HIV-1 RNA suppression.


  • Open Access

    Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection

    by David Nicolás, Anna Esteve, Anna Cuadros, Colin N. J. Campbell, Cristina Tural, Daniel Podzamczer, Javier Murillas, Francesc Homar, Ferrán Segura, Lluis Force, et al.

    Background. It has been suggested that routine CD4 cell count monitoring in human immunodeficiency virus (HIV)–monoinfected patients with suppressed viral loads and CD4 cell counts >300 cell/μL could be reduced to annual. HIV/hepatitis C virus (HCV) coinfection is frequent, but evidence supporting similar reductions in CD4 cell count monitoring is lacking for this population. We determined whether CD4 cell count monitoring could be reduced in monoinfected and coinfected patients by estimating the probability of maintaining CD4 cell counts ≥200 cells/µL during continuous HIV suppression. Methods. The PISCIS Cohort study included data from 14 539 patients aged ≥16 years from 10 hospitals in Catalonia and 2 in the Balearic Islands (Spain) since January 1998. All patients who had at least one period of 6 months of continuous HIV suppression were included in this analysis. Cumulative probabilities with 95% confidence intervals were calculated using the Kaplan–Meier estimator stratified by the initial CD4 cell count at the period of continuous suppression initiation. Results. A total of 8695 patients were included. CD4 cell counts fell to 350 cells/µL (1.8%) and higher in those with an initial count of 200–249 cells/µL (23.1%). CD4 cell counts fell to 350 cells/µL maintained counts ≥200 cells/µL. Conclusions. From our data, it can be inferred that CD4 cell count monitoring can be safely performed annually in HIV-monoinfected patients with CD4 cell counts >300 cells/µL and HIV/HCV-coinfected patients with counts >350 cells/µL.


  • Randomized trial of a multidisciplinary lifestyle intervention in HIV-infected patients with moderate-high cardiovascular risk

    by Maria Saumoy, Carlos Alonso-Villaverde, Antonio Navarro, Montserrat Olmo, Ramon Vila, Josep Maria Ramon, Silvana Di Yacovo, Elena Ferrer, Jordi Curto, Antonio Vernet, et al.


  • Open Access

    Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status

    by Elena Ferrer, Jordi Curto, Anna Esteve, Jose M. Miro, Cristina Tural, Javier Murillas, Ferran Segura, Pilar Barrufet, Jordi Casabona, Daniel Podzamczer

    The aim of this study was to analyse factors associated with progression to AIDS/death in severely immunosuppressed HIV-infected patients receiving ART. This study included naive patients from the PISCIS Cohort with CD4 18 years followed at 14 participating hospitals in Catalonia and the Balearic Islands (Spain). Clinical and laboratory parameters were assessed every 3–4 months during follow-up. Cox regression models were used to assess the effect of CD4 and viral load on the risk of progression to AIDS/death, adjusting for baseline variables and confounders. 2295 patients were included and, after 5 years, 69.9% reached CD4 ≥200 cells/mm3, 64.4% had an undetectable viral load and 482 (21%) progressed to AIDS/death. The lowest rate of disease progression was found in patients who reached both immunological and viral responses during follow-up, regardless of their baseline situation (1.9% in baseline CD4 >100 cells/mm3 and viral load 5 log copies/mL). Achieving a CD4 count ≥200 cells/mm3 was the main predictor of decreased progression to AIDS/death. In those not reaching this CD4 threshold, virological response reduced disease progression by half. Even in the worse baseline scenario of CD4 ≤100 cells/mm3 and high baseline viral loads, positive virological and immunological responses were associated with dramatic decreases in progression.


  • Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients

    by Eva Van Den Eynde, Jordi Curto, Elena Ferrer, Arkaitz Imaz, Maria Saumoy, Silvana Di Yacovo, Antonia Vila, Daniel Podzamczer

    We investigated kidney function outcome in 24 chronic hepatitis C genotype 1 patients coinfected with HIV receiving telaprevir in a single tertiary care hospital in Spain. A statistically significant median (interquartile range) decrease in estimated glomerular filtration rate (eGFR, ml/min/1.73 m2) relative to baseline [93.6 (73.0–109.0)] was seen at weeks 4 [86.5 (34.0–112.0), P = 0.014], 8 [90.0 (49.0–111.0), P = 0.026] and 12 [89.5 (54.0–113.0), P = 0.017]. These changes reversed after telaprevir discontinuation. Patients presenting an eGFR decrease had a higher risk of haematological toxicity.


  • Cerebrospinal Fluid and Plasma Lopinavir Concentrations and Viral Response in Virologically Suppressed Patients Switching to Lopinavir/Ritonavir Monotherapy Once Daily

    by Juan M Tiraboschi, Hernando Knobel, Arkaitz Imaz, Judith Villar, Elena Ferrer, Maria Saumoy, Alicia González, Nerea Rozas, Antonia Vila, Jordi Niubó, et al.

    Background: Lopinavir/ritonavir (LPV/r) monotherapy is used in selected virologically suppressed HIV-infected patients. Some would prefer a once-daily (OD) dose instead of the usual twice-daily dose to favour adherence. However, trough concentrations of the drug in blood and particularly in cerebrospinal fluid (CSF) may not be adequate to maintain viral suppression. Methods: Prospective, open-label pilot study to evaluate the efficacy and safety of LPV/r monotherapy OD. HIV-1-infected patients, virologically suppressed for at least 6 months were enrolled. HIV viral load (VL) was determined at baseline and at weeks 4, 8, 12, 16, 24, 36 and 48. Lumbar puncture was performed in a subgroup of patients to evaluate CSF VL and CSF LPV concentrations. Results: A total of 21 patients were included. At week 48, 85.7% ( n=18) showed viral suppression (VL<40 copies/ml). Two patients had viral failure (9.5%) and a third was withdrawn from the study because of gastrointestinal symptoms. Nine patients were enrolled in the substudy. CSF VL was <40 copies/ml in all cases. Median (range) LPV concentration was 9.78 ng/ml (1.93–78.3) in CSF and 1,970 (154–16,700) ng/ml in plasma; the CSF/plasma ratio was 0.004 (0.001–0.186). Conclusions: In this small pilot study, LPV/r monotherapy OD maintained plasma HIV RNA suppression at 48 weeks in most patients, with no cases of CSF viral escape. However, CSF LPV concentrations were close to the 50% inhibitory concentration threshold in several patients; hence, this intervention should be avoided in patients with advanced immune suppression and/or those individuals presenting with significant comorbidities such as hepatitis C coinfection.